Stocks
Nektar Therapeutics Financial Statements (NKTR) |
||||||||||
| Nektar Therapeuticssmart-lab.ru | % | 2020 | 2021 | 2022 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 26.02.2021 | 01.03.2022 | 31.12.2022 | 28.02.2023 | 05.03.2024 | 08.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 152.9 | 101.9 | 92.1 | 92.1 | 90.1 | 93.1 | |||
| Operating Income, bln rub | -379.9 | -446.1 | -376.2 | -240.2 | -137.4 | -135.9 | ||||
| EBITDA, bln rub | ? | -394.3 | -463.0 | -325.5 | -323.9 | -243.1 | -142.1 | |||
| Net profit, bln rub | ? | -444.4 | -523.8 | -368.2 | -368.2 | -276.1 | -168.3 | |||
| OCF, bln rub | ? | -313.3 | -412.7 | -304.0 | -304.0 | -192.6 | -176.6 | |||
| CAPEX, bln rub | ? | 7.26 | 15.0 | 5.68 | 5.68 | 0.865 | 1.25 | |||
| FCF, bln rub | ? | -320.5 | -427.6 | -309.7 | -309.7 | -193.5 | -177.8 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 513.4 | 523.1 | 310.7 | 310.7 | 190.9 | 199.0 | ||||
| Cost of production, bln rub | 19.5 | 24.9 | 21.6 | 21.6 | 36.6 | 30.0 | ||||
| R&D, bln rub | 408.7 | 400.3 | 218.3 | 218.3 | 111.3 | 122.1 | ||||
| Interest expenses, bln rub | 37.1 | 47.3 | 28.9 | 28.9 | 25.3 | 24.8 | ||||
| Assets, bln rub | 1 539 | 1 117 | 710.6 | 710.6 | 398.0 | 308.0 | ||||
| Net Assets, bln rub | ? | 1 077 | 679.5 | 366.6 | 366.6 | 131.0 | 48.9 | |||
| Debt, bln rub | 150.3 | 143.2 | 131.5 | 131.5 | 230.4 | 108.3 | ||||
| Cash, bln rub | 1 062 | 734.0 | 505.0 | 505.0 | 303.6 | 244.5 | ||||
| Net debt, bln rub | -911.6 | -590.8 | -373.5 | -373.5 | -73.2 | -136.2 | ||||
| Ordinary share price, rub | 17.0 | 13.5 | 2.26 | 2.26 | 0.565 | 0.490 | ||||
| Number of ordinary shares, mln | 178.6 | 183.3 | 187.1 | 187.1 | 190.0 | 209.2 | ||||
| Market cap, bln rub | 3 036 | 2 476 | 423 | 423 | 107 | 103 | ||||
| EV, bln rub | ? | 2 124 | 1 886 | 49 | 49 | 34 | -34 | |||
| Book value, bln rub | 1 001 | 603 | 290 | 290 | 131 | 49 | ||||
| EPS, rub | ? | -2.49 | -2.86 | -1.97 | -1.97 | -1.45 | -0.80 | |||
| FCF/share, rub | -1.79 | -2.33 | -1.65 | -1.65 | -1.02 | -0.85 | ||||
| BV/share, rub | 5.60 | 3.29 | 1.55 | 1.55 | 0.69 | 0.23 | ||||
| EBITDA margin, % | ? | -257.9% | -454.3% | -353.6% | -351.8% | -269.8% | -152.6% | |||
| Net margin, % | ? | -290.6% | -514.0% | -400.0% | -400.0% | -306.3% | -180.7% | |||
| FCF yield, % | ? | -10.6% | -17.3% | -73.2% | -73.2% | -180.2% | -173.4% | |||
| ROE, % | ? | -41.3% | -77.1% | -100.4% | -100.4% | -210.8% | -344.3% | |||
| ROA, % | ? | -28.9% | -46.9% | -51.8% | -51.8% | -69.4% | -54.6% | |||
| P/E | ? | -6.83 | -4.73 | -1.15 | -1.15 | -0.39 | -0.61 | |||
| P/FCF | -9.47 | -5.79 | -1.37 | -1.37 | -0.55 | -0.58 | ||||
| P/S | ? | 19.9 | 24.3 | 4.59 | 4.59 | 1.19 | 1.10 | |||
| P/BV | ? | 3.03 | 4.11 | 1.46 | 1.46 | 0.82 | 2.10 | |||
| EV/EBITDA | ? | -5.39 | -4.07 | -0.15 | -0.15 | -0.14 | 0.24 | |||
| Debt/EBITDA | 2.31 | 1.28 | 1.15 | 1.15 | 0.30 | 0.96 | ||||
| R&D/CAPEX, % | 5 631% | 2 670% | 3 846% | 3 846% | 12 865% | 9 800% | ||||
| CAPEX/Revenue, % | 4.75% | 14.7% | 6.17% | 6.17% | 0.96% | 1.34% | ||||
| Nektar Therapeutics shareholders | ||||||||||
